Outlook Therapeutics, Inc. (OTLK)

Market Cap	86.56M
Revenue (ttm)	n/a
Net Income (ttm)	21.12M
Shares Out	42.85M
EPS (ttm)	0.83
PE Ratio	2.44
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	924,089
Open	1.970
Previous Close	1.950
Day's Range	1.920 - 2.030
52-Week Range	0.870 - 9.250
Beta	0.26
Analysts	Strong Buy
Price Target	9.60 (+375.25%)
Earnings Date	Aug 13, 2025

About OTLK

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company was formerly known as Oncobiologics, Inc. and change...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 13, 2016
• Employees: 23
• Stock Exchange: NASDAQ
• Ticker Symbol: OTLK
• Website: https://www.outlooktherapeutics.com

Analyst Summary

According to 5 analysts, the average rating for OTLK stock is "Strong Buy." The 12-month stock price target is $9.6, which is an increase of 375.25% from the latest price.

Price Target

$9.6

(375.25% upside)

Analyst Consensus: Strong Buy